LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

Stock News08-03

Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.

On August 3, the company announced that China's National Medical Products Administration (NMPA) had granted Investigational New Drug (IND) approval for its self-developed candidate, Weilisin (PD-L1/4-1BB bispecific antibody, LBL-024), for the treatment of metastatic colorectal cancer (mCRC).

The approved trial is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of Weilisin in combination therapy for mCRC.

This milestone marks a significant expansion of the drug's indications in gastrointestinal cancers, extending the company's immuno-oncology pipeline from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) into colorectal cancer (CRC), a field with high unmet clinical need.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122893332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 10:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122893332","market":"sg","top_or_hot":-1,"title":"LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment","media":"Stock News","content":"<p>Shares of <b>LEADS BIOLABS-B (09887)</b> rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.<br><br>On August 3, the company announced that China's National Medical Products Administration (NMPA) had granted Investigational New Drug (IND) approval for its self-developed candidate, Weilisin (PD-L1/4-1BB bispecific antibody, LBL-024), for the treatment of metastatic colorectal cancer (mCRC).<br><br>The approved trial is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of Weilisin in combination therapy for mCRC.<br><br>This milestone marks a significant expansion of the drug's indications in gastrointestinal cancers, extending the company's immuno-oncology pipeline from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) into colorectal cancer (CRC), a field with high unmet clinical need.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-03 10:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>LEADS BIOLABS-B (09887)</b> rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.<br><br>On August 3, the company announced that China's National Medical Products Administration (NMPA) had granted Investigational New Drug (IND) approval for its self-developed candidate, Weilisin (PD-L1/4-1BB bispecific antibody, LBL-024), for the treatment of metastatic colorectal cancer (mCRC).<br><br>The approved trial is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of Weilisin in combination therapy for mCRC.<br><br>This milestone marks a significant expansion of the drug's indications in gastrointestinal cancers, extending the company's immuno-oncology pipeline from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) into colorectal cancer (CRC), a field with high unmet clinical need.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1122893332","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122893332","pubTimestamp":1785724340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.On August 3, the company announced that China's National Medical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","BK4585":"ETF&股票定投概念","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","IND":"Xtrackers Nifty 500 India ETF","09887":"维立志博-B","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","VXUS":"国际股票ETF-Vanguard"},"translate_title":"PD-L1/4-1BB 双特异性抗体获得 IND 批准用于晚期结直肠癌治疗，LEADS BIOLABS-B 股价上涨近 6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IND":1,"VXUS":1,"09887":1,"KCAI":1},"content_text":"Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.On August 3, the company announced that China's National Medical Products Administration (NMPA) had granted Investigational New Drug (IND) approval for its self-developed candidate, Weilisin (PD-L1/4-1BB bispecific antibody, LBL-024), for the treatment of metastatic colorectal cancer (mCRC).The approved trial is an open-label, multicenter Phase Ib/II study designed to evaluate the safety and efficacy of Weilisin in combination therapy for mCRC.This milestone marks a significant expansion of the drug's indications in gastrointestinal cancers, extending the company's immuno-oncology pipeline from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) into colorectal cancer (CRC), a field with high unmet clinical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122893332","isCrawlerRequest":true}